Liposomes containing an ASP49-phospholipase A 2 from Bothrops jararacussu snake venom as experimental therapy against cutaneous leishmaniasis

Barros, Neuza Biguinati de; Macedo, Sharon Rose Aragão; Ferreira, Amália S.; Tagliari, Monika Piazzon; Zanchi, Fernando Berton; Kayano, Anderson M.; Soares, Andreimar M.; Nicolete, Roberto

doi:10.1016/j.intimp.2016.04.025

Cited by 17 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advances in nanocarriers for the formulation of venom peptides include, especially, an improved ability to bypass membranes, better absorption by alternative routes such as oral and nasal, increased selective cytotoxicity of peptides (e.g., antitumor peptides), reduced toxicity toward normal cells, and increased half-life. In Table 2 [84][85][86][87][88][89][90][91][92][93][94][95][96][97][98], examples from the literature of venom-derived peptides formulated with…”

Section: Nanocarriers In the Cargo-delivery Of Venom-derived Peptidesmentioning

confidence: 99%

“…Liposomes also reduced the growth of amastigote forms within peritoneal macrophages of mice, demonstrating their selective leishmanicidal activity inside cells. This seems to be a promising armamentarium against leishmaniasis, in which the parasites are killed whereas host cells are undamaged [98]. From the venom of the monocled cobra Naja kaouthia, a 6.76 kDa toxin (NKCT1) that displays an anticancer effect, was conjugated with gold nanoparticles and showed increased antitumor effect compared to free toxin [12].…”

Section: Leishmanicidal Activity Liposomesmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticles Functionalized with Venom-Derived Peptides and Toxins for Pharmaceutical Applications

Santos

Araújo

Rádis‐Baptista

2020

CPB

View full text Add to dashboard Cite

Venom-derived peptides display diverse biological and pharmacological activities, making them useful in drug discovery platforms and for a wide range of applications in medicine and pharmaceutical biotechnology. Due to their target specificities, venom peptides have the potential to be developed into biopharmaceuticals to treat various health conditions such as diabetes mellitus, hypertension, and chronic pain. Despite the high potential for drug development, several limitations preclude the direct use of peptides as therapeutics and hamper the process of converting venom peptides into pharmaceuticals. These limitations include, for instance, chemical instability, poor oral absorption, short halflife, and off-target cytotoxicity. One strategy to overcome these disadvantages relies on the formulation of bioactive peptides with nanocarriers. A range of biocompatible materials are now available that can serve as nanocarriers and can improve the bioavailability of therapeutic and venom-derived peptides for clinical and diagnostic application. Examples of isolated venom peptides and crude animal venoms that have been encapsulated and formulated with different types of nanomaterials with promising results are increasingly reported. Based on the current data, a wealth of information can be collected regarding the utilization of nanocarriers to encapsulate venom peptides and render them bioavailable for pharmaceutical use. Overall, nanomaterials arise as essential components in the preparation of biopharmaceuticals that are based on biological and pharmacological active venom-derived peptides.

show abstract

Section: Nanocarriers In the Cargo-delivery Of Venom-derived Peptidesmentioning

confidence: 99%

Section: Leishmanicidal Activity Liposomesmentioning

confidence: 99%

Nanoparticles Functionalized with Venom-Derived Peptides and Toxins for Pharmaceutical Applications

Santos

Araújo

Rádis‐Baptista

2020

CPB

View full text Add to dashboard Cite

show abstract

“…Half of the animals in each group were sacrificed 72 h after the challenge. The amount of nitric oxide produced and released in the serum of the mice was determined by the Griess assay using the procedure described [9].…”

Section: Nitric Oxide and Specific Antibody Production In Immunized Mouse Serummentioning

confidence: 99%

Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania (L.) amazonensis in experimental cutaneous leishmaniasis model

Ribeiro

Ferreira

Macedo

et al. 2017

International Immunopharmacology

Self Cite

View full text Add to dashboard Cite

American tegumentary leishmaniasis (ATL) is considered a neglected disease, for which an effective vaccine or an efficient diagnosis is not yet available and whose chemotherapeutic arsenal is threatened by the emergence of resistance by etiological agents such as Leishmania amazonensis. ATL is endemic in poor countries and has a high incidence in Brazil. Vaccines developed from native parasite fractions have led to the identification of defined antigenic subunits and the development of vaccine adjuvant technology. The purpose of the present study was to develop and compare preparations based on membrane antigens from L. amazonensis, as a biotechnological prototype for the immunoprophylaxis of the disease in a murine experimental model. For this purpose, batches of biodegradable polymeric micro/nanoparticles were produced, characterized and compared with other parasite's antigens in solution. All preparations containing membrane antigens presented low toxicity on murine macrophages. The in vivo evaluation of immunization efficacy was performed against a challenge with L. amazonensis, along with an evaluation of the immune response profile generated in BALB/C mice. The animals were followed for sample processing and quantification of serum-specific cytokines, nitrites and antibodies. The sera of animals immunized with the non-encapsulated antigen formulations showed higher intensities of nitrites and total IgGs. This approach evidenced the importance of the biological studies involving the immune response of the host against the parasite being interconnected and related to the subfractionation of its proteins in the search for more effective vaccine candidates.

show abstract

“…PLA 2 toxins isolated from elapid and viperid snake venoms have been reported to cause muscle necrosis [8][9][10][11][12][13][14][15][16], induction of inflammatory cytokines [9,12,15,[17][18][19][20][21], neurotoxicity [15,[22][23][24][25], edema [9,14,18,19,21], hypotension [26], vasoconstriction [27], hemolysis [28], pulmonary congestion [12], intraperitoneal bleeding [12], and acute kidney injury [29]. Some snake venom PLA 2 s have been reported to have potential therapeutic activities including anti-cancer [30][31][32][33][34][35], anti-angiogenic [36], antibacterial [37,38], antiparasite [39], antithrombotic [40], anticoagulant [8,12,28,…”

Section: Introductionmentioning

confidence: 99%

Isolation and Characterization of A2-EPTX-Nsm1a, a Secretory Phospholipase A2 from Malaysian Spitting Cobra (Naja sumatrana) Venom

Abdullah

Rusmili

Abidin

et al. 2021

Toxins

View full text Add to dashboard Cite

Phospholipase A2 (PLA2) toxins are one of the main toxin families found in snake venom. PLA2 toxins are associated with various detrimental effects, including neurotoxicity, myotoxicity, hemostatic disturbances, nephrotoxicity, edema, and inflammation. Although Naja sumatrana venom contains substantial quantities of PLA2 components, there is limited information on the function and activities of PLA2 toxins from the venom. In this study, a secretory PLA2 from the venom of Malaysian N. sumatrana, subsequently named A2-EPTX-Nsm1a, was isolated, purified, and characterized. A2-EPTX-Nsm1a was purified using a mass spectrometry-guided approach and multiple chromatography steps. Based on LC-MSMS, A2-EPTX-Nsm1a was found to show high sequence similarity with PLA2 from venoms of other Naja species. The PLA2 activity of A2-EPTX-Nsm1 was inhibited by 4-BPB and EDTA. A2-EPTX-Nsm1a was significantly less cytotoxic in a neuroblastoma cell line (SH-SY5Y) compared to crude venom and did not show a concentration-dependent cytotoxic activity. To our knowledge, this is the first study that characterizes and investigates the cytotoxicity of an Asp49 PLA2 isolated from Malaysian N. sumatrana venom in a human neuroblastoma cell line.

show abstract

Liposomes containing an ASP49-phospholipase A 2 from Bothrops jararacussu snake venom as experimental therapy against cutaneous leishmaniasis

Cited by 17 publications

References 32 publications

Nanoparticles Functionalized with Venom-Derived Peptides and Toxins for Pharmaceutical Applications

Nanoparticles Functionalized with Venom-Derived Peptides and Toxins for Pharmaceutical Applications

Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania (L.) amazonensis in experimental cutaneous leishmaniasis model

Isolation and Characterization of A2-EPTX-Nsm1a, a Secretory Phospholipase A2 from Malaysian Spitting Cobra (Naja sumatrana) Venom

Contact Info

Product

Resources

About